Research › Fact Sheets › JNJ

JOHNSON & JOHNSON

LISTEDNYSE

SYMBOLJNJ

SIC2834

STATE OF INC.NJ

FISCAL YEAR ENDSJanuary 3

CIK200406

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2017–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/28/25

($ millions)	Amount	%
Total debt	49,933	38.0
Stockholders' equity	81,544	62.0
Total capitalization	131,477	100.0

2,409,898,597 shares outstanding at 17 July 2026 (cover page of the 10-Q filed 23 July 2026).

LONG-TERM DEBT 12/28/25

($ millions)	Amount
Long-term debt, incl. current maturities	41,438
Long-term debt, noncurrent	39,438
Current maturities	2,000
Short-term borrowings / commercial paper	8,495

CAPITAL STOCK 12/28/25

Common shares authorized	4,320,000,000
Common shares issued	3,119,843,000
Treasury shares	711,904,000
Par or stated value per share ($)	1
Preferred stock ($ millions)	0
Outstanding at 7/17/26	2,409,898,597

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	5.14	46.6
2024	4.91	84.8
2023	4.70	34.3
2023	4.45	66.1
2022	4.19	53.6

HISTORY AND BUSINESS

HISTORY: Incorporated in New Jersey. Formerly known as JOHNSON & JOHNSON ET AL (to 23 January 1996).

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: One Johnson & Johnson Plz, New Brunswick, NJ 08933. Fiscal year ends January 3. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/28/25	12/29/24	12/31/23
Revenues	94,193	88,821	85,159
Cost of revenues	30,256	27,471	26,553
Gross profit	63,937	61,350	58,606
Research and development	109	1,841	483
Selling, general and administrative	23,676	22,869	21,512
Depreciation and amortization	7,503	7,339	7,486
Interest expense	971	755	772
Income before income taxes	32,581	16,687	15,062
Income taxes	5,777	2,621	1,736
Net income	26,804	14,066	35,153
Earned per share, diluted ($)	11.03	5.79	13.72
Dividends per share ($)	5.14	4.91	4.70

CONSOLIDATED BALANCE SHEET

($ millions)	12/28/25	12/29/24
Cash and equivalents	19,709	24,105
Receivables, net	17,178	14,842
Inventories	14,191	12,444
Total current assets	55,624	55,893
Property, plant and equipment, net	23,169	20,518
Goodwill	48,772	44,200
Total assets	199,210	180,104
Total current liabilities	54,126	50,321
Long-term debt	39,438	30,651
Total liabilities	117,666	108,614
Total liabilities and equity	199,210	180,104

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/28/25	94,193	–	26,804	28.5	11.03	5.14	24,530	4,832	19,698	199,210	117,666	49,933	81,544	32.9	0.61
12/29/24	88,821	–	14,066	15.8	5.79	4.91	24,266	4,424	19,842	180,104	108,614	38,383	71,490	19.7	0.54
12/31/23	85,159	–	35,153	41.3	13.72	4.70	22,791	4,543	18,248	167,558	98,784	30,801	68,774	51.1	0.45
1/1/23	79,990	–	17,941	22.4	6.73	4.45	21,194	4,009	17,185	187,378	110,574	41,193	76,804	23.4	0.54
1/2/22	78,740	–	20,878	26.5	7.81	4.19	23,410	3,652	19,758	182,018	107,995	35,882	74,023	28.2	0.48
1/3/21	82,584	–	14,714	17.8	5.51	3.98	23,536	3,347	20,189	174,894	111,616	37,065	63,278	23.3	0.59
12/29/19	82,059	–	15,119	18.4	5.63	3.75	23,416	3,498	19,918	157,728	98,257	28,896	59,471	25.4	0.49
12/30/18	81,581	–	15,297	18.8	5.61	3.54	22,201	3,670	18,531	152,954	93,202	33,080	59,752	25.6	0.55
12/31/17	76,450	–	1,300	1.7	0.47	3.32	21,056	3,279	17,777	157,303	97,143	36,081	60,160	2.2	0.60
1/1/17	71,890	–	16,540	23.0	5.93	3.15	18,767	3,226	15,541	141,208	70,790	28,826	70,418	23.5	0.41

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

JOHNSON & JOHNSON
CIK 200406 · EIN 22-1024240

PRINCIPAL OFFICE:

One Johnson & Johnson Plz, New Brunswick, NJ 08933
Tel.: 732-524-2455

INCORPORATED:

New Jersey

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/28/25, filed 11 February 2026

FORMER NAMES:

JOHNSON & JOHNSON ET AL

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

10/13/26	8-K	period 10/13/26
8/4/26	8-K	period 8/4/26
7/29/26	8-K	period 7/29/26
7/28/26	8-K	period 7/27/26
7/23/26	10-Q	period 6/28/26
7/15/26	8-K	period 7/15/26
4/28/26	8-K	period 4/23/26
4/22/26	10-Q	period 3/29/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/11/26) · 10-K FY2024 (filed 2/13/25) · 10-K FY2023 (filed 2/16/24) · 10-K FY2022 (filed 2/16/23) · 10-K FY2021 (filed 2/17/22) · 10-K FY2020 (filed 2/22/21) · 10-K FY2019 (filed 2/18/20) · 10-K FY2018 (filed 2/20/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.